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Abstract: Type 1 Gaucher disease is a rare genetic lysosomal disorder due to acid betaglucosidase
deficiency. The main features are thrombocytopenia, anemia, hepatosplenomegaly and complex
skeletal disease. Complications include pulmonary hypertension, cirrhosis and splenic infarction;
comorbidities, such as autoimmune phenomena, B-cell malignancies and Parkinson disease also occur.
Visceral aneurysms have been only rarely noted in Gaucher disease. We report the retrospective
data from patients with Gaucher disease type 1 and splenic arterial aneurysm. We describe the
different outcomes of a giant splenic arterial aneurysm in five patients with type 1 Gaucher disease
and discuss the main possible pathophysiological explanations. Aneurysms of the splenic artery are
rare in Gaucher disease but are probably greatly under-reported.
Keywords: Gaucher disease; lysosomal storage disorder; splenic arterial aneuryms; enzyme
replacement therapy
1. Introduction
Gaucher disease (GD) is a rare inborn error of lysosomal metabolism characterized by lysosomal
storage of the sphingolipid, β-glucosylceramide. GD is due to the deficiency of a lysosomal enzyme,
acid beta-glucosidase (or glucocerebrosidase) [1] or in rare cases of its activator, saposin C [2]. The
disease incidence is around 1/50,000 births in the general population and 1/800 births in Ashkenazi
Jewish population [3,4]. GD diagnosis is confirmed by showing low acid-β-glucosidase activity (<30%)
in peripheral leucocytes [5]. Mutations in the gene, GBA1, encoding β-glucosylceramidase disable the
enzyme and β-glucosylceramide accumulates within macrophages [6].
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Three different subtypes of GD are recognized: type 1 GD (GD1) is characterized by
thrombocytopenia, anemia, an enlarged spleen and liver—as well as bone complications (Erlenmeyer
flask deformity, osteoporosis, lytic lesions, pathological and vertebral fractures, bone infarcts and
avascular necrosis leading to degenerative arthropathy) [7]. GD1 represents 90% of cases in Western
countries. Type 2 GD is the acute infantile neuronopathic form, which progresses rapidly and causes
death within the first year or two of life [8]. Type 3, or chronic neuronopathic GD, is a “catch all”
encompassing patients who survive infancy but have highly variable but progressive neurological
involvement. In reality these phenotypes overlap, and GD is now viewed as a disease continuum [9].
GD1 may be complicated by pulmonary hypertension, cirrhosis, splenic infarction or rupture,
several cancers and/or Parkinson disease. Splenic artery aneurysms (SAAs) have been little recognized.
The splenic artery is defined as aneurysmal when a focal dilatation is observed and its diameter greater
than 50% of the normal vessel diameter. SAAs account for more than half of all visceral aneurysms and
are the third most frequent intra-abdominal aneurysms [10]. True SAAs involve all layers of the arterial
wall, each of which is intact but attenuated. Pseudoaneurysms are the result of a tear in the vessel
wall with dissection of the intima: these may be the consequence of trauma or inflammation of the
splenic artery. Small SAAs (≤2 cm) are usually asymptomatic, but giant SAAs (≥5 cm) are more likely
to cause symptoms and can result in life-threatening complications. Hypertension, atherosclerosis,
cirrhosis, portal hypertension, liver transplantation, female sex (with pregnancy and multiparity) and
connective tissue disorder such as Marfan or Ehlers-Danlos syndromes are recognized associations.
Although splenomegaly in GD has been associated with SAAs, a bibliographic review identified
only two reports of this complication [11]. We report the retrospective data from five patients with
GD1 and SAA. All the patients have abdominal imagery (ultrasonography, CT scan or MRI) according
to the recommendations for GD1. All the patients gave their informed consent. Ethics approval was
not required for these case reports.
Three men and two women with GD1 were diagnosed with SAA. Patient characteristics are set
out in Table 1.
Table 1. Characteristics of patients with aneurysms of the splenic artery.
Patient Sex/Age
Age at
Diagnosis
of GD
Genotype Treatment
Age at
Diagnosis
of SAA
Evolution
1 F, NA 30 N370S/N370S
Intermittent ERT 10 U/kg
eow from 44 to
52-year-old
63
Sudden collapse
and death aged
63 years
2 F, 59 19 N370S/84GG ERT 16 U/kg eow 49 Complex set offour SAA
3 M, 50 10 N370S/N370S ERT 60 U/kg eow at40-year-old 40
Aneurism size
increase
4 M, 62 38 N370S/D218A
ERT 75 U/kg every three
weeks from 45 to
48-year-old
58 Embolizationtwo years later
5 M, 31 29 N370S/K196E
ERT 60 U/kg/eow at
29-year-old then
eliglustat at 30-year-old
29 Aneurism sizestabilization
F, female; M, male; eow: every other week, ERT: enzyme replacement therapy, SAA: splenic artery aneurysm.
The patients had splenomegaly and moderate thrombocytopenia at the diagnosis of GD but in
one patient detailed records of diagnosis were not found. Four out of five had bone manifestations
at the diagnosis of GD (Erlenmeyer flask deformity, bone infarcts and bone marrow infiltration).
Three patients had received enzyme replacement therapy (ERT) before the diagnosis of SAA. One
patient (Patient 1) was treated between 1993 and 1999 but for personal reasons stopped the therapy;
in this patient SAA was identified post mortem after an acute and catastrophic intraabdominal
hemorrhage. One patient stopped ERT after three years. Two patients started the treatment after the
SAA was discovered.
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ERT improved the platelet count and splenomegaly in all the patients so treated. SAA diameter
was 40 mm for patient 2, 30 mm for patient 3 (Figure 1), 29 mm for patient 4 and 24 mm for patient 5.
SAA size increased for patient 3 (+6 mm between 2009 and 2018 despite ERT) and was stable for two
patients (patients 4 and 5).
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micro aneurysms.
Patient 1 died rapidly after bleeding, w ich occurred while she was awaiti g an underground
trai . Coroner’s post-mortem was decisive: there was massive blood loss int the abdomen with a
10 × 15 cm collection in the splenic bed. The spleen itself was firm and int ct: the onl abnormali y
was a dilated th n-walled arterial aneurysm at the hilum of the spleen indicating a true SAA. Patient 2
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2. Discussion
The prevalence of SAA associated with GD in this study is 2% (5 patients out of 252 GD1
patients followed in these 4 centers) whereas the prevalence in the general population is extremely
variable between 1% [12] to 10.4% in necropsy series [13]. However, this prevalence must be
considered with cautiousness as in GD1, such an aneurysm can be underdiagnosed with abdominal
ultrasonography. Indeed, a total splenic artery exploration is quite difficult due to their deep course
and the gut superpositions, especially if the aneurysm is not in the hilum. Moreover, in GD, due to the
splenomegaly it is frequent to observe a tortuous splenic artery with loops making the diagnosis of
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SAA difficult. Similarly, SAAs may be underdiagnosed in the general population because they are
often asymptomatic [14]. To our knowledge, only two cases of splenic arterial aneurysm associated
with GD1 have been reported in the literature in 1989 [11]. Recently Reynolds et al. described a patient
with multiple intracerebral aneurysms and GD1 [15]. Nasu et al. described an annulo-aortic ectasia
with type II dissecting aneurysm in a Gaucher patient [16]. However, as illustrated here, SAAs are not
unusual during the course of this disease.
Most of those reported here were asymptomatic or initially asymptomatic, except for those
occurring in the two women: (1) the first, who was a patient found to have the condition at post
mortem examination after rupture, had a thankfully brief symptomatic period as fatal hemorrhagic
shock supervened; (2) the other woman, complained of worsening pain in the left hypochondrium
and had mild local tenderness. While this patient had frequently complained of mid pain in the
region over many years and had been known to have at least one aneurysm, the changed character
of the symptoms and their provocation by external jolting movements, led to magnetic resonance
(MR) angiography at which several large aneurysms were detected (the largest at >4 cm diameter).
By this time, a vascular surgical opinion was sought urgently, and curative splenectomy rather than
embolization was successfully carried out with good symptom relief. These events are consistent with
what is known for other SAAs: True splenic arterial aneurysms are asymptomatic until they expand to
merit classification as giant or near-giant; they are often diagnosed by means of advanced imaging
techniques [17]. We contend that on account of their potential for expansion and rupture SAAs should
be searched for actively in patients with Gaucher disease.
In those patients with optimal responses to sustained enzyme therapy as illustrated by
patients 4 and 5, aneurysmal size appears not to have changed–albeit with follow-up of only two years.
As to causation, we suggest that the most plausible pathophysiological explanation may be the
effects of greatly increased arterial flow attributable to often marked and sustained splenomegaly
in this chronic genetic disease. As in pregnancy, or other cases in which massive splenomegaly is
sustained, or in the presence of portal venous hypertension, arterial blood flow is likely to become
turbulent, exerting strong sheer forces on the inner wall of the artery, as it traverses the constitutively
tortuous splenic vessel. Of note three out of five of the patients reported here had no symptoms or signs
indicating portal hypertension, and in two cases, SAA was diagnosed despite salutary spleen volume
response to ERT. An alternative, or perhaps additional mechanism, would be a change in arterial wall
structure and function due to infiltration with pathological macrophages known as Gaucher cells, as
has been reported in some patients within pulmonary hypertension that complicates rare cases of
GD [18]. So far however, in two of the patients histological material was available and this did not
confirm such pathology in the arterial wall.
All these patients were heterozygous for the most usual mutation in GD1, the N370S mutation.
However, we cannot conclude that SAA were related to this mutation.
While we are not able to speculate on the impact of targeted Gaucher-specific therapies for GD1
on the behavior of the aneurysms but, it is notable that three patients out of five had no ERT at the time
the aneurysm was detected. On first principles, we can suppose that reducing the volume of the spleen
would be beneficial so reducing flow, sheer forces and pressure effects in the artery. However, for
patient 3 aneurysm diameter increased despite a reduction in spleen volume. The other male patient
was successfully treated by splenic artery embolization.
3. Conclusions
Aneurysms of the splenic artery are rare in Gaucher disease but are probably greatly
under-reported. However, since imaging, including abdominal ultrasonography and/or MR is
conducted periodically in many patients receiving specialist care for their Gaucher disease, we contend
that more scrupulous examinations and monitoring of aneurysmal behavior is indicated. This will
improve knowledge of the course of the condition and is likely to prevent adverse outcomes and pain
from intrabdominal pressure effects or even arterial rupture. Despite the absence of consensus on the
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therapeutic management of these aneurysms and particularly those associated with GD, spectacular
progress in radiological techniques has been made—alongside improving treatment choices in Gaucher
disease. A coordinated initiative in the field may facilitate risk stratification and determine whether
aneurysms arising in a particular context or disease stage will expand and whether specific therapy
can mitigate this hazard.
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